Vimarsana
Biggest News Aggregation in the World

Page 3 - Complete Enrollment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Complete Enrollment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Complete Enrollment Today - Breaking & Trending Today

Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results - Vimarsana News

Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Sierra Oncology Reports First Quarter 2021 Results - Vimarsana News

Sierra Oncology Reports First Quarter 2021 Results

Sierra Oncology Reports First Quarter 2021 Results News provided by Share this article – Topline Data Now Expected in Q1 2022 – SAN MATEO, Calif., May 7, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2021. "The first quarter of 2021 has been a hugely productive one for Sierra. We are excited to share that MOMENTUM enrollment has accelerated, and we now anticipate completing enrollment...

Sierra Oncology Reports 2020 Year End Results - Vimarsana News

Sierra Oncology Reports 2020 Year End Results

Sierra Oncology Reports 2020 Year End Results News provided by Share this article Share this article – MOMENTUM Phase 3 Trial on Track to Complete Enrollment in mid-2021 with Top-line Data Anticipated in H1 2022 – – Data Presented Throughout the Year Included Long-Term Overall Survival, Efficacy in Various Patient Subsets and Dosing Durability – – Key Appointments Made to Executive Team in Preparation for Commercial Execution – SAN MATEO, Calif., March 11, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted thera...